Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

protein-engineered interleukin-2 XTX202

A modified form of the recombinant form of human endogenous cytokine interleukin-2 (IL-2), that is masked with a protein domain, with potential immunoregulatory and antineoplastic activities. Upon administration of protein-engineered IL-2 XTX202, IL-2 is bound to the protein and pharmacologically inactive. IL-2 does not become active until cleaved by specific proteases in the tumor microenvironment (TME). Upon proteolytic cleavage, unbound and active IL-2 locally binds to the IL-2 receptor beta (CD122) and gamma (CD132) subunits (IL2Rb/g) that are expressed on CD8+ T-effector cells and natural killer (NK) cells, thereby activating IL2R-mediated signaling within these immune cells. The activation of T cells and NK cells mediate cytolytic immune responses against tumor cells causing tumor cell destruction and inhibition of tumor cell proliferation. XTX202 does not bind to IL-2 receptor alpha (IL-2Ra) and does not cause IL-2Ra-mediated toxicities. The selective activation in the TME enhances the IL-2-mediated cytolytic responses against tumor cells while sparing the unwanted effects of systemic, peripheral immune activation.
Synonym:engineered IL-2 prodrug XTX202
modified IL-2 XTX202
protein-engineered IL-2 XTX202
tumor-selective IL-2 XTX202
Code name:XTX 202
XTX-202
Search NCI's Drug Dictionary